Role of decorin in the antimyeloma effects of osteoblasts
Role of decorin in the antimyeloma effects of osteoblasts
复制标题
DOI：
10.1182/blood-2007-11-124164
复制
发表时间：
2008-07-01
期刊：
影响因子：
20.3
通讯作者：
Yaccoby, Shmuel
中科院分区：
文献类型：
--
作者：
Li, Xin;Pennisi, Angela;Yaccoby, Shmuel
基于我们之前的报告，即成骨细胞和骨形成增加对一部分患者的骨髓瘤细胞生长有负面影响，我们研究了核心蛋白聚糖（由成骨细胞表达和产生的主要小亮氨酸蛋白聚糖（SLRP））在成骨细胞抗骨髓瘤作用中的作用。在与成骨细胞的共培养实验中，当成骨细胞中的核心蛋白聚糖表达被短发夹RNA敲低时，原发性骨髓瘤细胞的存活率显著较高。骨髓瘤细胞和支持破骨细胞在成骨细胞条件培养基存在下的共培养实验显示骨髓瘤细胞存活率降低，核心蛋白聚糖中和抗体减弱了这种作用。核心蛋白聚糖在间充质干细胞中过表达或重组核心蛋白聚糖与破骨细胞共培养降低了破骨细胞支持原发性骨髓瘤细胞存活的能力。核心蛋白聚糖的抗骨髓瘤作用涉及直接诱导细胞凋亡和激活p21（WAF）。核心蛋白聚糖还抑制骨髓瘤细胞诱导的管形成和破骨细胞分化。核心蛋白聚糖的表达在患者的成骨细胞中并不显著低于供体的成骨细胞，硼替佐米略微增加。某些SLRP通过抑制血管生成和破骨细胞生成直接和间接参与成骨细胞的抗骨髓瘤作用;因此，增加骨髓瘤骨中的内源性或外源性SLRP可能有助于控制骨髓瘤。
Building on our previous report that osteoblasts and increased bone formation have a negative impact on myeloma cell growth in a subset of patients, we investigated the role of decorin, the main small leucine-rich proteoglycan (SLRP) expressed and produced by osteoblasts, in the antimyeloma effects of osteoblasts. In coculture experiments with osteoblasts, primary myeloma cell survival was significantly higher when decorin expression in osteoblasts was knocked down by short-hairpin RNA. Coculture experiments of myeloma cells and supporting osteoclasts in the presence of osteoblast-conditioned medium showed reduced myeloma cell survival, an effect that was attenuated by decorin-neutralizing antibody. Decorin overexpression in mesenchymal stem cells or use of recombinant decorin in coculture with osteoclasts reduced the ability of osteoclasts to support primary myeloma cell survival. The antimyeloma effect of decorin involved direct induction of apoptosis and activation of p21(WAF). Decorin also inhibited myeloma cell-induced tube formation and osteoclast differentiation. Decorin expression was insignificantly lower in patients' than donors' osteoblasts and slightly increased by bortezomib. Certain SLRPs are involved in the antimyeloma effect of osteoblasts directly and indirectly through inhibition of angiogenesis and osteoclastogenesis; therefore, increasing endogenous or exogenous SLRPs in myelomatous bone may help control myeloma.